- Home
- NVRI vs PHAR Comparison
NVRI vs PHAR Comparison
Compare NVRI & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVRI
- PHAR
- Stock Information
- Founded
- NVRI 1853
- PHAR 1988
- Country
- NVRI United States
- PHAR Netherlands
- Employees
- NVRI N/A
- PHAR N/A
- Industry
- NVRI Diversified Commercial Services
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- NVRI Miscellaneous
- PHAR Health Care
- Exchange
- NVRI Nasdaq
- PHAR Nasdaq
- Market Cap
- NVRI 572.2M
- PHAR 679.0M
- IPO Year
- NVRI N/A
- PHAR N/A
- Fundamental
- Price
- NVRI $9.45
- PHAR $9.55
- Analyst Decision
- NVRI Hold
- PHAR Strong Buy
- Analyst Count
- NVRI 1
- PHAR 3
- Target Price
- NVRI $10.00
- PHAR $27.00
- AVG Volume (30 Days)
- NVRI 1.4M
- PHAR 5.4K
- Earning Date
- NVRI 02-27-2025
- PHAR 03-13-2025
- Dividend Yield
- NVRI N/A
- PHAR N/A
- EPS Growth
- NVRI N/A
- PHAR N/A
- EPS
- NVRI N/A
- PHAR N/A
- Revenue
- NVRI $2,086,473,000.00
- PHAR $285,745,000.00
- Revenue This Year
- NVRI $16.52
- PHAR $20.08
- Revenue Next Year
- NVRI $0.21
- PHAR $9.22
- P/E Ratio
- NVRI N/A
- PHAR N/A
- Revenue Growth
- NVRI N/A
- PHAR 30.64
- 52 Week Low
- NVRI $6.57
- PHAR $6.65
- 52 Week High
- NVRI $12.79
- PHAR $13.20
- Technical
- Relative Strength Index (RSI)
- NVRI 80.46
- PHAR 50.97
- Support Level
- NVRI $8.32
- PHAR $9.37
- Resistance Level
- NVRI $8.89
- PHAR $10.01
- Average True Range (ATR)
- NVRI 0.32
- PHAR 0.52
- MACD
- NVRI 0.11
- PHAR -0.10
- Stochastic Oscillator
- NVRI 93.89
- PHAR 28.08
About NVRI Enviri Corporation
Enviri Corp engages in providing a broad range of environmental services and related solutions. The company's current operations consist of three divisions: Harsco Environmental, Harsco Rail, and Clean Earth. The company serves a diverse customer base by offering critical recycle and reuse solutions for their waste streams, enabling customers to address their complex environmental challenges.
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.